Search
Close this search box.

A Decade of Arvinas

arvn-10annv-mask-group-2-dtp

Forging New Scientific Frontiers in Drug Discovery

2023 marked a monumental milestone in Arvinas’ history as we celebrated our 10-year anniversary.

Over the past decade, Arvinas has made incredible strides in pioneering targeted protein degradation research.

From creating the first oral PROTAC® protein degraders for clinical trials, to the initiation of Phase 3 clinical studies, we’ve remained committed to pushing the boundaries of what’s possible in biotech.

arvn-10annv-mask-group-1-dtp
arvn-10annv-mask-group-2-dtp
arvn-10annv-arvinas_labs_2022-99-dtp

1O Years of Scientific Discovery

2O13

Arvinas is founded by Yale professor Craig Crews with the goal of turning PROTAC® protein degraders into patient therapies

2O16

Arvinas creates the first oral PROTAC® protein degraders for clinical trial evaluation

2O18

Arvinas creates the first blood-brain barrier-crossing PROTAC® protein degraders

2O19

Two Arvinas PROTAC® degraders, bavdegalutamide and vepdegestrant, enter clinical studies

2O2O

Proof of concept is achieved for bavdegalutamide and vepdegestrant

2O21

Arvinas partners with Pfizer to co-develop and co-commercialize vepdegestrant

2O22

Arvinas initiates first registrational study with vepdegestrant

Bavdegalutamide and vepdegestrant are currently under investigation. Their safety and effectiveness have not yet been established.

1O Years of Scientific Discovery

1O Years of Scientific Discovery

2023
2O22
2O22

Arvinas initiates first registrational study with vepdegestrant

2O19

Arvinas PROTAC® degraders, bavdegalutamide and vepdegestrant, enter clinical studies

2020

Efficacy proof of concept is achieved for bavdegalutamide and vepdegestrant

2021

Arvinas partners with Pfizer to co-develop and co-commercialize vepdegestrant

2OO1

Arvinas’ founder, Craig Crews, publishes the first paper describing heterobifunctional protein degraders

2O13

Arvinas is founded with the goal to turn protein degraders into patient therapies

2016

Arvinas creates the first oral PROTAC® protein degrader

2O18

Arvinas creates the first blood-brain barrier-crossing PROTAC® protein degrader

Bavdegalutamide and vepdegestrant are currently under investigation.
Their safety and effectiveness have not yet been established.

image001

Team Arvinas: Stories of Discovery and Impact

We are incredibly proud of the milestones we have achieved thus far. But don’t just take our word for it— hear firsthand from Arvinas colleagues as they reflect on our remarkable journey.

200x200
image001
Breaking Barriers in Biotech: The Arvinas Founding Story
Craig Crews, Ph.D, Founder
Turning a Crazy Idea into Game-Changing Technology
Andy Crew, Ph.D, Former Head of Chemistry and Chief Technology Officer
Driving a Decade of Excellence in Drug Discovery
John Houston, Ph.D, Chairperson, President, and Chief Executive Officer
Chasing the Undruggable and Changing Lives
Ian Taylor, Ph.D, Chief Scientific Officer
Bringing a Business Brain to Biotech
Sean Cassidy, C.P.A., Chief Financial Officer
Working Hard, Experimenting, and Taking Risks
Tim Shannon, M.D., Former Chairperson of the Board of Directors
Celebrating a Decade of Career Growth
Xin Chen, Senior Director, Analytical R&D
Making a Dream a Reality
Hanqing Dong, Ph.D, Senior Director, Chemistry
Embracing the Unknown
Alicia Morgan, Senior Research Scientist, Platform Biology
A Culture of Care: Putting People First
Katie Smith, Ph.D, Principal Senior Research Investigator
Learning From Remarkable Scientists
Sachita Ganesa, Ph.D, Senior Research Scientist, Neuroscience
Embracing Innovation and Commitment  
Sheryl Gough, Ph.D, Principal Research Investigator
Fostering Personal and Professional Growth
Diana Alicea, Executive Assistant to the Chairperson, President and Chief Executive Officer
arvn-10annv-mask-group-45-mob

What’s Next: Looking Towards the Future

We couldn’t be more excited about the future of our company! Take a closer look at those shaping the future of Arvinas and driving us toward even greater success.

Smiling Arvinas scientific staff member talking with colleague
Arvinas scientific staff
arvn-cta-disc-03

If you’re inspired, please take a look at the current list of opportunities to join our team.

Search
Close this search box.

Arvinas

You are now leaving arvinas.com. Arvinas does not endorse or recommend the content in any third-party sites. Arvinas is not responsible and disclaims liability for the content, or for any viruses or similar harmful programs, that may be present on third-party pages or sites. Visits to a third-party website are at your own risk and subject to the terms and conditions and privacy policy of such site.

Skip to content